LDLR

Across TCGA pan-cancer cohorts, LDLR Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated LDLR data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher LDLR Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LDLR expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

OV, HNSC, and SCLC are the cancer types where LDLR Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	IV	0.007	0.760	<.001	30	view →
HNSC	DFS	Median	All	0.147	0.697	<.001	27	view →
SCLC	OS	Median	II,III,IV	0.055	0.702	<.001	24	view →
LUSC	OS	Median	IV	0.001	0.673	.014	18	view →
LUAD	OS	Median	II,III,IV	0.158	0.750	<.001	18	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
UCEC	OS	Median	II,III,IV	0.928	0.461	.036	8	view →
PRAD	DFS	Median	All	0.617	0.886	.045	6	view →
STAD	OS	Median	III,IV	0.003	0.630	<.001	6	view →
ACC	DFS	Median	All	0.140	0.666	.049	3	view →
SKCM	DFS	Median	III,IV	0.764	0.245	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

LDLR–OV (OS)

Open the OV breakdown →